{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T09:52:44Z","timestamp":1791280364411,"version":"4.1.0"},"reference-count":242,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacc.2026.05.033","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T20:12:12Z","timestamp":1782850332000},"page":"1255-1283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement"],"prefix":"10.1016","volume":"88","author":[{"given":"Dharam J.","family":"Kumbhani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasia L.","family":"Armbruster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard K.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Chrispin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Urs","family":"Fischer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne Marie","family":"Holbrook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Joglar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Antoinette","family":"Sevestre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacc.2026.05.033_bib1","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.amjcard.2013.05.063","article-title":"Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population","volume":"112","author":"Colilla","year":"2013","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101330","article-title":"Prevalence, management, and comorbidities of adults with atrial fibrillation in the United States, 2019 to 2023","volume":"3","author":"Oltman","year":"2024","journal-title":"JACC Adv"},{"key":"10.1016\/j.jacc.2026.05.033_bib3","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.jacc.2022.11.060","article-title":"Initial findings from the national cardiovascular data registry of atrial fibrillation ablation procedures","volume":"81","author":"Hsu","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib4","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.033_bib5","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.105.595140","article-title":"Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence","volume":"114","author":"Miyasaka","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.033_bib6","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1161\/01.STR.22.8.983","article-title":"Atrial fibrillation as an independent risk factor for stroke: the Framingham Study","volume":"22","author":"Wolf","year":"1991","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2026.05.033_bib7","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000068743","article-title":"Atrial fibrillation is associated with severe acute ischemic stroke","volume":"22","author":"Dulli","year":"2003","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.jacc.2026.05.033_bib8","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1136\/jnnp.2004.048827","article-title":"Atrial fibrillation as a predictive factor for severe stroke and early death in 15,831 patients with acute ischaemic stroke","volume":"76","author":"Kimura","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.jacc.2026.05.033_bib9","article-title":"Atrial fibrillation and risks of cardiovascular disease, renal disease, and death: systematic review and meta-analysis","volume":"354","author":"Odutayo","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2026.05.033_bib10","doi-asserted-by":"crossref","first-page":"e347","DOI":"10.1161\/CIR.0000000000001209","article-title":"2024 heart disease and stroke statistics: a report of US and global data from the American Heart Association","volume":"149","author":"Martin","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.033_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.hrthm.2004.10.042","article-title":"Relationship between atrial tachyarrhythmias and symptoms","volume":"2","author":"Strickberger","year":"2005","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2026.05.033_bib12","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1212\/01.wnl.0000325059.86313.31","article-title":"Atrial fibrillation detected by mobile cardiac outpatient telemetry in cryptogenic TIA or stroke","volume":"71","author":"Tayal","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.jacc.2026.05.033_bib13","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1001\/jama.2021.6470","article-title":"Effect of long-term continuous cardiac monitoring vs usual care on detection of atrial fibrillation in patients with stroke attributed to large- or small-vessel disease: the STROKE-AF randomized clinical trial","volume":"325","author":"Bernstein","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.033_bib14","doi-asserted-by":"crossref","first-page":"492","DOI":"10.7326\/0003-4819-131-7-199910050-00003","article-title":"Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis","volume":"131","author":"Hart","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib15","doi-asserted-by":"crossref","first-page":"2441","DOI":"10.1001\/jama.288.19.2441","article-title":"Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis","volume":"288","author":"van Walraven","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.033_bib16","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1056\/NEJMoa1007432","article-title":"Apixaban in patients with atrial fibrillation","volume":"364","author":"Connolly","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib17","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.jacc.2023.08.017","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"83","author":"Joglar","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib18","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.020428","article-title":"Inpatient versus outpatient acute venous thromboembolism management: trends and postacute healthcare utilization from 2011 to 2018","volume":"10","author":"Lutsey","year":"2021","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.05.033_bib19","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1002\/rth2.12482","article-title":"Provoked versus unprovoked venous thromboembolism: Findings from GARFIELD-VTE","volume":"5","author":"Ageno","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.thromres.2022.11.016","article-title":"36-month clinical outcomes of patients with venous thromboembolism: GARFIELD-VTE","volume":"222","author":"Turpie","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2026.05.033_bib21","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jaccao.2023.09.003","article-title":"Cancer-associated thrombosis: trends in clinical features, treatment, and outcomes from 2001 to 2020","volume":"5","author":"Bertoletti","year":"2023","journal-title":"JACC CardioOncology"},{"key":"10.1016\/j.jacc.2026.05.033_bib22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"issue":"Suppl 1","key":"10.1016\/j.jacc.2026.05.033_bib23","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1538-7836.2011.04346.x","article-title":"Management of venous thromboembolism in patients with cancer","volume":"9","author":"Agnelli","year":"2011","journal-title":"J Thromb Haemost JTH"},{"key":"10.1016\/j.jacc.2026.05.033_bib24","doi-asserted-by":"crossref","first-page":"2299","DOI":"10.1093\/eurheartj\/ehab171","article-title":"Relative risk of arterial and venous thromboembolism in persons with cancer vs. persons without cancer-a nationwide analysis","volume":"42","author":"Grilz","year":"2021","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.033_bib25","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.amsu.2020.11.003","article-title":"The association between surgical duration and venous thromboembolism in outpatient surgery: a propensity score adjusted prospective cohort study","volume":"60","author":"Pence","year":"2020","journal-title":"Ann Med Surg"},{"key":"10.1016\/j.jacc.2026.05.033_bib26","doi-asserted-by":"crossref","first-page":"339.e19","DOI":"10.1016\/j.amjmed.2015.10.014","article-title":"Lifetime risk of venous thromboembolism in two cohort studies","volume":"129","author":"Bell","year":"2016","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1097\/MBC.0000000000001140","article-title":"Risk factors for recurrent venous thromboembolism: a real-world analysis","volume":"33","author":"Fu","year":"2022","journal-title":"Blood Coagul Fibrinolysis Int J Haemost Thromb"},{"key":"10.1016\/j.jacc.2026.05.033_bib28","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1016\/j.jvsv.2022.05.014","article-title":"Venous thromboembolism as the first sign of malignancy","volume":"10","author":"Pandit","year":"2022","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"key":"10.1016\/j.jacc.2026.05.033_bib29","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.026723","article-title":"Trends in oral anticoagulant use among 436 864 patients with atrial fibrillation in community practice, 2011 to 2020","volume":"11","author":"Navar","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.05.033_bib30","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1016\/S0735-1097(03)00416-9","article-title":"American Heart Association\/American College of Cardiology Foundation guide to warfarin therapy","volume":"41","author":"Hirsh","year":"2003","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib31","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1046\/j.1365-2125.1998.00721.x","article-title":"Cytochrome P4502C9: an enzyme of major importance in human drug metabolism","volume":"45","author":"Miners","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2026.05.033_bib32","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0140-6736(98)04474-2","article-title":"Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications","volume":"353","author":"Aithal","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.033_bib33","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1001\/jama.287.13.1690","article-title":"Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy","volume":"287","author":"Higashi","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.033_bib34","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/s41569-025-01144-z","article-title":"Factor XI inhibitors for the prevention and treatment of venous and arterial thromboembolism","volume":"22","author":"Capodanno","year":"2025","journal-title":"Nat Rev Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib35","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1080\/17425255.2023.2287472","article-title":"Pharmacokinetics and pharmacodynamics of direct oral anticoagulants","volume":"19","author":"Hindley","year":"2023","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.jacc.2026.05.033_bib36","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1111\/bjh.17470","article-title":"A universal anti-Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation","volume":"193","author":"Willekens","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jacc.2026.05.033_bib37","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1161\/ATVBAHA.110.203604","article-title":"Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin","volume":"30","author":"Eisert","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacc.2026.05.033_bib38","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1093\/eurheartj\/ehae176","article-title":"2024 ESC guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"45","author":"Van Gelder","year":"2024","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.033_bib39","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1161\/CIRCULATIONAHA.116.024057","article-title":"Wide variation in reported rates of stroke across cohorts of patients with atrial fibrillation","volume":"135","author":"Quinn","year":"2017","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.033_bib40","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.113.000250","article-title":"A new risk scheme to predict ischemic stroke and other thromboembolism in atrial fibrillation: the ATRIA study stroke risk score","volume":"2","author":"Singer","year":"2013","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.05.033_bib41","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2017-017157","article-title":"Improved risk stratification of patients with atrial fibrillation: an integrated GARFIELD-AF tool for the prediction of mortality, stroke and bleed in patients with and without anticoagulation","volume":"7","author":"Fox","year":"2017","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2026.05.033_bib42","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1161\/CIRCULATIONAHA.117.029081","article-title":"Female sex is a risk modifier rather than a risk factor for stroke in atrial fibrillation: should we use a CHA2DS2-VA score rather than CHA2DS2-VASc?","volume":"137","author":"Nielsen","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.033_bib43","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1161\/CIRCULATIONAHA.110.009035","article-title":"Absolute and attributable risks of atrial fibrillation in relation to optimal and borderline risk factors: the Atherosclerosis Risk In Communities (ARIC) study","volume":"123","author":"Huxley","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.033_bib44","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.115.002015","article-title":"Blood pressure control and risk of stroke or systemic embolism in patients with atrial fibrillation: results from the apixaban for reduction in stroke and other thromboembolic events in atrial fibrillation (ARISTOTLE) trial","volume":"4","author":"Rao","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.05.033_bib45","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.hrthm.2020.09.018","article-title":"Anticoagulation for stroke prevention in patients with hypertrophic cardiomyopathy and atrial fibrillation: a review","volume":"18","author":"Nasser","year":"2021","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2026.05.033_bib46","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1016\/j.athoracsur.2020.10.055","article-title":"Postoperative atrial fibrillation after cardiac surgery: a meta-analysis","volume":"112","author":"Woldendorp","year":"2021","journal-title":"Ann Thorac Surg"},{"key":"10.1016\/j.jacc.2026.05.033_bib47","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCEP.119.007716","article-title":"Initial precipitants and recurrence of atrial fibrillation","volume":"13","author":"Wang","year":"2020","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib48","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1056\/NEJMoa2509688","article-title":"Antithrombotic therapy after successful catheter ablation for atrial fibrillation","volume":"394","author":"Verma","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib49","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1001\/jama.2025.14679","article-title":"Long-term anticoagulation discontinuation after catheter ablation for atrial fibrillation: the ALONE-AF randomized clinical trial","volume":"334","author":"Kim","year":"2025","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.033_bib50","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa2310234","article-title":"Apixaban for stroke prevention in subclinical atrial fibrillation","volume":"390","author":"Healey","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib51","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1056\/NEJMoa2303062","article-title":"Anticoagulation with edoxaban in patients with atrial high-rate episodes","volume":"389","author":"Kirchhof","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib52","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jacc.2024.05.002","article-title":"Apixaban vs aspirin according to CHA2DS2-VASc score in subclinical atrial fibrillation: insights from ARTESiA","volume":"84","author":"Lopes","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib53","article-title":"Midregional proatrial natriuretic peptide to guide secondary stroke prevention: the MOSES-study. An international, multicentre, randomised-controlled, two-arm","author":"Katan","year":"2023","journal-title":"assessor-blinded trial"},{"key":"10.1016\/j.jacc.2026.05.033_bib54","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1177\/1747493018799981","article-title":"The atrial cardiopathy and antithrombotic drugs in prevention after cryptogenic stroke randomized trial: rationale and methods","volume":"14","author":"Kamel","year":"2019","journal-title":"Int J Stroke"},{"issue":"Suppl 3","key":"10.1016\/j.jacc.2026.05.033_bib55","first-page":"304","article-title":"Clinical assessment of venous thromboembolic risk in surgical patients","volume":"17","author":"Caprini","year":"1991","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib56","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1002\/bjs.5154","article-title":"Randomized clinical trial of postoperative fondaparinux versus perioperative dalteparin for prevention of venous thromboembolism in high-risk abdominal surgery","volume":"92","author":"Agnelli","year":"2005","journal-title":"Br J Surg"},{"key":"10.1016\/j.jacc.2026.05.033_bib57","doi-asserted-by":"crossref","first-page":"913","DOI":"10.1046\/j.0007-1323.2001.01800.x","article-title":"Meta-analysis of low molecular weight heparin in the prevention of venous thromboembolism in general surgery","volume":"88","author":"Mismetti","year":"2001","journal-title":"Br J Surg"},{"key":"10.1016\/j.jacc.2026.05.033_bib58","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.033_bib59","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.033_bib60","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa1006885","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after hip replacement","volume":"363","author":"Lassen","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib61","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib62","first-page":"1","article-title":"Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"Ginsberg","year":"2009","journal-title":"J Arthroplasty"},{"key":"10.1016\/j.jacc.2026.05.033_bib63","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib64","doi-asserted-by":"crossref","first-page":"3898","DOI":"10.1182\/bloodadvances.2019000975","article-title":"American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients","volume":"3","author":"Anderson","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacc.2026.05.033_bib65","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-060000","article-title":"Randomised comparative effectiveness trial of pulmonary embolism prevention after hiP and kneE replacement (PEPPER): the PEPPER trial protocol","volume":"12","author":"Pellegrini","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jacc.2026.05.033_bib66","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1056\/NEJMoa2209051","article-title":"Rivaroxaban in rheumatic heart disease-associated atrial fibrillation","volume":"387","author":"Connolly","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib67","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1709118","article-title":"Rivaroxaban with or without aspirin in stable cardiovascular disease","volume":"377","author":"Eikelboom","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib68","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300067","article-title":"Apixaban or warfarin in patients with an on-X mechanical aortic valve","volume":"2","author":"Wang","year":"2023","journal-title":"NEJM Evid"},{"key":"10.1016\/j.jacc.2026.05.033_bib69","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib70","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1093\/eurheartj\/ehac242","article-title":"Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial","volume":"43","author":"Collet","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.033_bib71","doi-asserted-by":"crossref","DOI":"10.1007\/s11239-025-03226-8","article-title":"Efficacy and safety of anticoagulant therapy for hypoattenuated leaflet thickening post-TAVR: a systematic review and meta-analysis","author":"Tudella","year":"2025","journal-title":"J Thromb Thrombolysis"},{"key":"10.1016\/j.jacc.2026.05.033_bib72","article-title":"Transcatheter mitral valve replacement for severe mitral annular calcification: primary outcomes from the SUMMIT-MAC study","author":"Sorajja","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib73","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.jacc.2021.08.060","article-title":"2-year outcomes of transcatheter mitral valve replacement in patients with severe symptomatic mitral regurgitation","volume":"78","author":"Muller","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib74","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa2401918","article-title":"Transcatheter valve replacement in severe tricuspid regurgitation","volume":"392","author":"Hahn","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib75","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib76","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/S0140-6736(12)62177-1","article-title":"Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial","volume":"381","author":"Dewilde","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.033_bib77","doi-asserted-by":"crossref","first-page":"2423","DOI":"10.1056\/NEJMoa1611594","article-title":"Prevention of bleeding in patients with atrial fibrillation undergoing PCI","volume":"375","author":"Gibson","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib78","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","article-title":"Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation","volume":"377","author":"Cannon","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib79","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0140-6736(19)31872-0","article-title":"Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial","volume":"394","author":"Vranckx","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.033_bib80","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1161\/CIRCULATIONAHA.112.115386","article-title":"Concomitant use of antiplatelet therapy with dabigatran or warfarin in the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial","volume":"127","author":"Dans","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.033_bib81","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.jacc.2023.04.003","article-title":"2023 AHA\/ACC\/ACCP\/ASPC\/NLA\/PCNA guideline for the management of patients with chronic coronary disease","volume":"82","author":"Virani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib82","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1016\/j.jacc.2024.11.009","article-title":"2025 ACC\/AHA\/ACEP\/NAEMSP\/SCAI guideline for the management of patients with acute coronary syndromes: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"85","author":"Rao","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib83","doi-asserted-by":"crossref","first-page":"2306","DOI":"10.1016\/j.jacc.2018.03.008","article-title":"Major adverse limb events and mortality in patients with peripheral artery disease: the COMPASS trial","volume":"71","author":"Anand","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib84","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1016\/j.jacc.2024.02.013","article-title":"2024 ACC\/AHA\/AACVPR\/APMA\/ABC\/SCAI\/SVM\/SVN\/SVS\/SIR\/VESS guideline for the management of lower extremity peripheral artery disease","volume":"83","author":"Gornik","year":"2024","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib85","doi-asserted-by":"crossref","first-page":"997","DOI":"10.7326\/0003-4819-129-12-199812150-00002","article-title":"Use of a clinical model for safe management of patients with suspected pulmonary embolism","volume":"129","author":"Wells","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib86","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1111\/j.1538-7836.2004.00790.x","article-title":"Clinical criteria to prevent unnecessary diagnostic testing in emergency department patients with suspected pulmonary embolism","volume":"2","author":"Kline","year":"2004","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib87","doi-asserted-by":"crossref","first-page":"165","DOI":"10.7326\/0003-4819-144-3-200602070-00004","article-title":"Prediction of pulmonary embolism in the emergency department: the revised Geneva score","volume":"144","author":"Le Gal","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib88","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.jacc.2025.11.005","article-title":"2026 AHA\/ACC\/ACCP\/ACEP\/CHEST\/SCAI\/SHM\/SIR\/SVM\/SVN guideline for the evaluation and management of acute pulmonary embolism in adults: a report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"87","author":"Creager","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib89","first-page":"1486","article-title":"New oral anticoagulants and the risk of intracranial hemorrhage: traditional and Bayesian meta-analysis and mixed treatment comparison of randomized trials of new oral anticoagulants in atrial fibrillation","volume":"70","author":"Chatterjee","year":"2013","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jacc.2026.05.033_bib90","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib91","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for the treatment of symptomatic pulmonary embolism","volume":"366","author":"B\u00fcller","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib92","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1056\/NEJMoa1302507","article-title":"Oral apixaban for the treatment of acute venous thromboembolism","volume":"369","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib93","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib94","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1056\/NEJMoa1306638","article-title":"Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism","volume":"369","author":"B\u00fcller","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib95","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacc.2026.05.033_bib96","doi-asserted-by":"crossref","first-page":"2045","DOI":"10.1160\/TH17-03-0176","article-title":"Dabigatran versus warfarin for acute venous thromboembolism in elderly or impaired renal function patients: pooled analysis of RE-COVER and RE-COVER II","volume":"117","author":"Goldhaber","year":"2017","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib97","doi-asserted-by":"crossref","first-page":"e379","DOI":"10.1016\/S2352-3026(16)30057-6","article-title":"Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial","volume":"3","author":"Raskob","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jacc.2026.05.033_bib98","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1001\/jamainternmed.2025.1109","article-title":"Oral anticoagulation and risk of adverse clinical outcomes in venous thromboembolism","volume":"185","author":"Bea","year":"2025","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib99","article-title":"Efficacy and safety of anticoagulants on venous thromboembolism: a systematic review and network meta-analysis of randomized controlled trials","volume":"15","author":"Fu","year":"2024","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacc.2026.05.033_bib100","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1056\/NEJMoa2510703","article-title":"Bleeding risk with apixaban vs. rivaroxaban in acute venous thromboembolism","volume":"394","author":"Castellucci","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib101","article-title":"Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study","volume":"356","author":"Rodger","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.jacc.2026.05.033_bib102","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1001\/jama.2015.7046","article-title":"Six months vs extended oral anticoagulation after a first episode of pulmonary embolism: the PADIS-PE randomized clinical trial","volume":"314","author":"Couturaud","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.033_bib103","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1056\/NEJMoa1700518","article-title":"Rivaroxaban or aspirin for extended treatment of venous thromboembolism","volume":"376","author":"Weitz","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib104","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMoa1207541","article-title":"Apixaban for extended treatment of venous thromboembolism","volume":"368","author":"Agnelli","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib105","article-title":"MAC project-monitoring anticoagulant therapy observational study: rationale and protocol","volume":"7","author":"Camporese","year":"2020","journal-title":"Front Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib106","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1056\/NEJMoa2509426","article-title":"Apixaban for extended treatment of provoked venous thromboembolism","volume":"393","author":"Piazza","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib107","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/S0140-6736(24)02842-3","article-title":"Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial","volume":"405","author":"Couturaud","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.033_bib108","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-02171-z","article-title":"Aspirin for the extended prevention of venous thromboembolism: a meta-analysis and trial sequential analysis","volume":"15","author":"Carron","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.jacc.2026.05.033_bib109","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJMoa1114238","article-title":"Aspirin for preventing the recurrence of venous thromboembolism","volume":"366","author":"Becattini","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib110","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1056\/NEJMoa1210384","article-title":"Low-dose aspirin for preventing recurrent venous thromboembolism","volume":"367","author":"Brighton","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib111","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018917","article-title":"Direct oral anticoagulants in patients with inherited thrombophilia and venous thromboembolism: a prospective cohort study","volume":"9","author":"Campello","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacc.2026.05.033_bib112","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.amjmed.2018.11.040","article-title":"Impact of prolonged anticoagulation with rivaroxaban on provoked venous thromboembolism recurrence: IMPROVE-VTE","volume":"132","author":"Coleman","year":"2019","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib113","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1111\/jth.14935","article-title":"Use of direct oral anticoagulants in patients with thrombotic antiphospholipid syndrome: guidance from the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis","volume":"18","author":"Zuily","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib114","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.jacc.2022.10.008","article-title":"Direct oral anticoagulants vs vitamin K antagonists in patients with antiphospholipid syndromes: meta-analysis of randomized trials","volume":"81","author":"Khairani","year":"2023","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib115","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/S1474-4422(24)00037-1","article-title":"Secondary stroke prevention in people with atrial fibrillation: treatments and trials","volume":"23","author":"Seiffge","year":"2024","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2026.05.033_bib116","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1056\/NEJMoa2303048","article-title":"Early versus later anticoagulation for stroke with atrial fibrillation","volume":"388","author":"Fischer","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib117","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(24)02197-4","article-title":"Optimal timing of anticoagulation after acute ischaemic stroke with atrial fibrillation (OPTIMAS): a multicentre, blinded-endpoint, phase 4, randomised controlled trial","author":"Werring","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.033_bib118","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1001\/jamaneurol.2025.0285","article-title":"Optimal delay time to initiate anticoagulation after ischemic stroke in atrial fibrillation: a pragmatic, response-adaptive randomized clinical trial","volume":"82","author":"Warach","year":"2025","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jacc.2026.05.033_bib119","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1161\/CIRCULATIONAHA.122.060666","article-title":"Early versus delayed non-vitamin K antagonist oral anticoagulant therapy after acute ischemic stroke in atrial fibrillation (TIMING): a registry-based randomized controlled noninferiority study","volume":"146","author":"Oldgren","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.033_bib120","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0140-6736(25)00439-8","article-title":"Collaboration on the optimal timing of anticoagulation after ischaemic stroke and atrial fibrillation: a systematic review and prospective individual participant data meta-analysis of randomised controlled trials (CATALYST)","volume":"406","author":"Dehbi","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.jacc.2026.05.033_bib121","article-title":"2026 guideline for the early management of patients with acute ischemic stroke: a guideline from the American Heart Association\/American Stroke Association","volume":"2026","author":"Prabhakaran","year":"2026","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2026.05.033_bib122","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.ijcard.2022.06.065","article-title":"Clinical outcomes of left atrial appendage occlusion versus direct oral anticoagulation in patients with atrial fibrillation and prior ischemic stroke: a propensity-score matched study","volume":"363","author":"Korsholm","year":"2022","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib123","doi-asserted-by":"crossref","DOI":"10.1111\/ene.70387","article-title":"Cardioembolic breakthrough stroke: when anticoagulation fails, is left atrial appendage closure the next step?","volume":"32","author":"Palaiodimou","year":"2025","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jacc.2026.05.033_bib124","doi-asserted-by":"crossref","DOI":"10.1177\/17562864251406065","article-title":"Safety and efficacy of oral anticoagulation in patients with intracranial hemorrhage and atrial fibrillation: a systematic review and meta-analysis of randomized controlled clinical trials","volume":"18","author":"Papageorgiou","year":"2025","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.jacc.2026.05.033_bib125","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1093\/ndt\/gfv009","article-title":"Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis","volume":"30","author":"Masson","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jacc.2026.05.033_bib126","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1016\/j.jacc.2016.06.057","article-title":"Atrial fibrillation and thromboembolism in patients with chronic kidney disease","volume":"68","author":"Lau","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib127","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1161\/STROKEAHA.120.028934","article-title":"Direct-acting oral anticoagulants versus warfarin in Medicare patients with chronic kidney disease and atrial fibrillation","volume":"51","author":"Wetmore","year":"2020","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2026.05.033_bib128","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1016\/j.kint.2023.10.018","article-title":"KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"105","year":"2024","journal-title":"Kidney Int"},{"key":"10.1016\/j.jacc.2026.05.033_bib129","doi-asserted-by":"crossref","first-page":"2241","DOI":"10.1681\/ASN.2016090980","article-title":"Apixaban pharmacokinetics at steady state in hemodialysis patients","volume":"28","author":"Mavrakanas","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"10.1016\/j.jacc.2026.05.033_bib130","doi-asserted-by":"crossref","first-page":"259","DOI":"10.2165\/11318170-000000000-00000","article-title":"Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study","volume":"49","author":"Stangier","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.jacc.2026.05.033_bib131","doi-asserted-by":"crossref","first-page":"2888","DOI":"10.1016\/j.jacc.2016.02.082","article-title":"Nonvitamin K anticoagulant agents in patients with advanced chronic kidney disease or on dialysis with AF","volume":"67","author":"Chan","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib132","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ejim.2023.08.020","article-title":"Efficacy and safety of direct oral anticoagulants vs vitamin K antagonists in patients with atrial fibrillation and end-stage renal disease on hemodialysis: A systematic review and meta-analysis","volume":"119","author":"Kyriakoulis","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib133","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jacc.2019.04.061","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation and history of liver disease","volume":"74","author":"Qamar","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib134","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/hep.31264","article-title":"Mortality and hepatic decompensation in patients with cirrhosis and atrial fibrillation treated with anticoagulation","volume":"73","author":"Serper","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.jacc.2026.05.033_bib135","doi-asserted-by":"crossref","first-page":"f84","DOI":"10.1093\/ehjcvp\/pvaa015","article-title":"Impact of liver disease on oral anticoagulant prescription and major adverse events in patients with atrial fibrillation: analysis from a population-based cohort study","volume":"7","author":"Proietti","year":"2021","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2026.05.033_bib136","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.ijcard.2018.01.097","article-title":"Incidence of bleeding in patients with atrial fibrillation and advanced liver fibrosis on treatment with vitamin K or non-vitamin K antagonist oral anticoagulants","volume":"264","author":"Pastori","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib137","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1053\/j.gastro.2021.09.004","article-title":"AGA technical review on coagulation in cirrhosis","volume":"161","author":"Intagliata","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jacc.2026.05.033_bib138","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1093\/ehjcvp\/pvab032","article-title":"Anticoagulation in atrial fibrillation and liver disease: a pooled-analysis of >20 000 patients","volume":"8","author":"Chen","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"10.1016\/j.jacc.2026.05.033_bib139","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40256-021-00482-w","article-title":"Comparison of the efficacy and safety of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation and concomitant liver cirrhosis: a systematic review and meta-analysis","volume":"22","author":"Lee","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacc.2026.05.033_bib140","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1007\/s40256-023-00598-1","article-title":"Direct oral anticoagulants versus vitamin K antagonists in cirrhotic patients with atrial fibrillation: update of systematic review and meta-analysis","volume":"23","author":"Hu","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jacc.2026.05.033_bib141","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1007\/s00228-024-03648-y","article-title":"Recommendations for the safe use of direct oral anticoagulants in patients with cirrhosis based on a systematic review of pharmacokinetic, pharmacodynamic and safety data","volume":"80","author":"Diesveld","year":"2024","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2026.05.033_bib142","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.jacc.2013.09.070","article-title":"Frailty assessment in the cardiovascular care of older adults","volume":"63","author":"Afilalo","year":"2014","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib143","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.117.031658","article-title":"Oral anticoagulation in very elderly patients with atrial fibrillation: a nationwide cohort study","volume":"138","author":"Chao","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.033_bib144","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.7326\/M20-7141","article-title":"Frailty and clinical outcomes of direct oral anticoagulants versus warfarin in older adults with atrial fibrillation: a cohort study","volume":"174","author":"Kim","year":"2021","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib145","doi-asserted-by":"crossref","DOI":"10.1007\/s11357-025-01936-8","article-title":"Frailty elements, direct oral anticoagulants and mortality risk in atrial fibrillation patients aged \u2265 80 or \u2265 90 years from the nationwide Italian START registry: a propensity score matching analysis","author":"Menichelli","year":"2025","journal-title":"GeroScience"},{"key":"10.1016\/j.jacc.2026.05.033_bib146","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","article-title":"Low-dose edoxaban in very elderly patients with atrial fibrillation","volume":"383","author":"Okumura","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib147","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jacc.2025.05.060","article-title":"Outcomes in older patients after switching to a newer anticoagulant or remaining on warfarin: the COMBINE-AF substudy","volume":"86","author":"Nicolau","year":"2025","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib148","first-page":"279","article-title":"Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial","volume":"149","author":"Joosten","year":"2024","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.033_bib149","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1161\/CIRCULATIONAHA.118.037955","article-title":"Efficacy and safety of apixaban versus warfarin in patients with atrial fibrillation and extremes in body weight","volume":"139","author":"Hohnloser","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.033_bib150","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1093\/eurheartj\/ehy861","article-title":"Relationship between body mass index and outcomes in patients with atrial fibrillation treated with edoxaban or warfarin in the ENGAGE AF-TIMI 48 trial","volume":"40","author":"Boriani","year":"2019","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacc.2026.05.033_bib151","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/j.amjcard.2017.03.028","volume":"119","author":"Balla","year":"2017","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib152","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.2044","article-title":"Safety and efficacy of direct oral anticoagulants in comparison to warfarin in obese patients with atrial fibrillation: a systematic review and meta-analysis","volume":"7","author":"Adelkhanova","year":"2024","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.jacc.2026.05.033_bib153","doi-asserted-by":"crossref","first-page":"3784","DOI":"10.3390\/jcm13133784","article-title":"Efficacy and safety of direct oral anticoagulants versus warfarin in obese patients (BMI \u2265 30 kg\/m2) with atrial fibrillation or venous thromboembolism: an updated systematic review and meta-analysis","volume":"13","author":"Karakasis","year":"2024","journal-title":"J Clin Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib154","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1055\/a-1588-9155","article-title":"Oral anticoagulant use in patients with morbid obesity: a systematic review and meta-analysis","volume":"122","author":"Wang","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib155","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1111\/jth.15358","article-title":"Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC Subcommittee on Control of Anticoagulation","volume":"19","author":"Martin","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib156","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/jth.15823","article-title":"Direct oral anticoagulants after bariatric surgery-what is the evidence?","volume":"20","author":"Leong","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib157","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1161\/CIRCULATIONAHA.111.055079","article-title":"Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial fibrillation cohort study","volume":"125","author":"Friberg","year":"2012","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.033_bib158","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1016\/j.jacep.2019.07.011","article-title":"Ischemic and bleeding outcomes in patients with atrial fibrillation and contraindications to oral anticoagulation","volume":"5","author":"Steinberg","year":"2019","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib159","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1161\/STROKEAHA.121.036757","article-title":"Effectiveness and safety of anticoagulation therapy in frail patients with atrial fibrillation","volume":"53","author":"Kim","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.jacc.2026.05.033_bib160","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.ijcard.2018.03.053","article-title":"Restarting oral anticoagulant therapy after major bleeding in atrial fibrillation: a systematic review and meta-analysis","volume":"261","author":"Proietti","year":"2018","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib161","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1016\/j.chest.2018.07.040","article-title":"Antithrombotic therapy for atrial fibrillation: CHEST guideline and expert panel report","volume":"154","author":"Lip","year":"2018","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2026.05.033_bib162","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/j.jacc.2017.07.724","article-title":"Cerebral amyloid angiopathy: diagnosis, clinical implications, and management strategies in atrial fibrillation","volume":"70","author":"DeSimone","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib163","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/S1474-4422(23)00315-0","article-title":"Effects of oral anticoagulation in people with atrial fibrillation after spontaneous intracranial haemorrhage (COCROACH): prospective, individual participant data meta-analysis of randomised trials","volume":"22","author":"Al-Shahi Salman","year":"2023","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.jacc.2026.05.033_bib164","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1177\/17474930251360076","article-title":"Left atrial appendage occlusion in patients with atrial fibrillation and previous intracranial hemorrhage or cerebral amyloid angiopathy: a systematic review and meta-analysis","volume":"20","author":"Mavridis","year":"2025","journal-title":"Int J Stroke"},{"key":"10.1016\/j.jacc.2026.05.033_bib165","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.jacc.2026.05.033_bib166","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jacc.2012.06.019","volume":"60","author":"Apostolakis","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib167","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.757087","article-title":"Diagnostic accuracy of the HAS-BLED bleeding score in VKA- or DOAC-treated patients with atrial fibrillation: a systematic review and meta-analysis","volume":"8","author":"Gao","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib168","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1111\/jth.14692","article-title":"Accuracy of HAS-BLED and other bleeding risk assessment tools in predicting major bleeding events in atrial fibrillation: a network meta-analysis","volume":"18","author":"Chang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib169","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1161\/CIRCULATIONAHA.123.064556","article-title":"Development and validation of the DOAC score: a novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants","volume":"148","author":"Aggarwal","year":"2023","journal-title":"Circulation"},{"key":"10.1016\/j.jacc.2026.05.033_bib170","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejim.2024.06.022","article-title":"Performance of HAS-BLED and DOAC scores to predict major bleeding events in atrial fibrillation patients treated with direct oral anticoagulants: a report from a prospective European observational registry","volume":"128","author":"Mei","year":"2024","journal-title":"Eur J Intern Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib171","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.amjmed.2021.01.031","article-title":"Increasing incidence and declining mortality after cancer-associated venous thromboembolism: a nationwide cohort study","volume":"134","author":"Ording","year":"2021","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib172","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2026.05.033_bib173","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO clinical practice guideline update","volume":"38","author":"Key","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jacc.2026.05.033_bib174","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1111\/jth.15074","article-title":"Management of hemostatic complications in acute leukemia: guidance from the SSC of the ISTH","volume":"18","author":"Wang","year":"2020","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib176","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1111\/jth.14219","article-title":"Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH","volume":"16","author":"Khorana","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib177","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1182\/bloodadvances.2020001501","article-title":"Clinical characteristics, management, and outcome of incidental pulmonary embolism in cancer patients","volume":"4","author":"Qdaisat","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacc.2026.05.033_bib178","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.thromres.2023.05.027","article-title":"Incidence of recurrent venous thromboembolism and bleeding complications in patients with cancer and isolated distal deep vein thrombosis","volume":"228","author":"Brown","year":"2023","journal-title":"Thromb Res"},{"key":"10.1016\/j.jacc.2026.05.033_bib179","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1111\/jth.15416","article-title":"Outcome of anticoagulation in isolated distal deep vein thrombosis compared to proximal deep venous thrombosis","volume":"19","author":"Vlazny","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib180","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-022-01289-1","article-title":"Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials","volume":"15","author":"Frere","year":"2022","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.jacc.2026.05.033_bib181","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jacc.2026.05.033_bib182","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1055\/s-0040-1720975","article-title":"Bleeding with apixaban and dalteparin in patients with cancer-associated venous thromboembolism: results from the Caravaggio study","volume":"121","author":"Ageno","year":"2021","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib183","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a Randomized Trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jacc.2026.05.033_bib184","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the treatment of cancer-associated venous thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib185","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1183\/13993003.00280-2016","article-title":"Prediction of bleeding events in patients with venous thromboembolism on stable anticoagulation treatment","volume":"48","author":"Klok","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jacc.2026.05.033_bib186","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1056\/NEJMoa2416112","article-title":"Extended reduced-dose apixaban for cancer-associated venous thromboembolism","volume":"392","author":"Mah\u00e9","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.jclinane.2024.111556","article-title":"Incidence and onset of central venous catheter-related thrombosis in critically ill surgical patients: a prospective observational single-center study","volume":"97","author":"Gibb","year":"2024","journal-title":"J Clin Anesth"},{"key":"10.1016\/j.jacc.2026.05.033_bib188","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1111\/jth.12071","article-title":"International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer","volume":"11","author":"Debourdeau","year":"2013","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib189","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jacc.2021.01.049","article-title":"Comparative study of oral anticoagulation in left ventricular thrombi (no-LVT trial)","volume":"77","author":"Abdelnabi","year":"2021","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib190","doi-asserted-by":"crossref","first-page":"82","DOI":"10.4244\/EIJ-D-24-00527","article-title":"Direct oral anticoagulants or warfarin in patients with left ventricular thrombus after ST-elevation myocardial infarction: a pilot trial and a prespecified meta-analysis of randomised trials","volume":"21","author":"Jenab","year":"2025","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacc.2026.05.033_bib191","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jacc.2016.11.024","article-title":"2017 ACC expert consensus decision pathway for periprocedural management of anticoagulation in patients with nonvalvular atrial fibrillation: a report of the American College of Cardiology Clinical Expert Consensus Document Task Force","volume":"69","author":"Doherty","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib192","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1001\/jamainternmed.2019.2431","article-title":"Perioperative management of patients with atrial fibrillation receiving a direct oral anticoagulant","volume":"179","author":"Douketis","year":"2019","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib193","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1056\/NEJMoa1302946","article-title":"Pacemaker or defibrillator surgery without interruption of anticoagulation","volume":"368","author":"Birnie","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib194","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1111\/pace.14091","article-title":"Continued versus interrupted direct oral anticoagulation for cardiac electronic device implantation: a systematic review","volume":"43","author":"Mendoza","year":"2020","journal-title":"Pacing Clin Electrophysiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib195","doi-asserted-by":"crossref","first-page":"2964","DOI":"10.1016\/j.jacc.2017.10.021","article-title":"5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials","volume":"70","author":"Reddy","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib196","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.jacc.2022.02.047","article-title":"Antithrombotic therapy after left atrial appendage occlusion in patients with atrial fibrillation","volume":"79","author":"Freeman","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib197","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.122.012812","article-title":"Antithrombotic management after left atrial appendage closure: current evidence and future perspectives","volume":"16","author":"Mesnier","year":"2023","journal-title":"Circ Cardiovasc Interv"},{"key":"10.1016\/j.jacc.2026.05.033_bib198","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.jacc.2022.04.062","article-title":"Impact of peridevice leak on 5-year outcomes after left atrial appendage closure","volume":"80","author":"Dukkipati","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib199","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1016\/j.jacep.2018.09.007","article-title":"Incidence and clinical impact of device-related thrombus following percutaneous left atrial appendage occlusion: a meta-analysis","volume":"4","author":"Alkhouli","year":"2018","journal-title":"JACC Clin Electrophysiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib200","doi-asserted-by":"crossref","first-page":"877","DOI":"10.4244\/EIJ-D-17-00042","article-title":"Safety and efficacy of early anticoagulation drug regimens after WATCHMAN left atrial appendage closure: three-month data from the EWOLUTION prospective, multicentre, monitored international WATCHMAN LAA closure registry","volume":"13","author":"Bergmann","year":"2017","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacc.2026.05.033_bib201","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1001\/jamacardio.2024.2335","article-title":"Low-dose direct oral anticoagulation vs dual antiplatelet therapy after left atrial appendage occlusion: the ADALA randomized clinical trial","volume":"9","author":"Freixa","year":"2024","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib202","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.4244\/EIJ-D-16-00726","article-title":"Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy","volume":"12","author":"Korsholm","year":"2017","journal-title":"EuroIntervention"},{"key":"10.1016\/j.jacc.2026.05.033_bib203","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1002\/joa3.13082","article-title":"2024 European Heart Rhythm Association\/Heart Rhythm Society\/Asia Pacific Heart Rhythm Society\/Latin American Heart Rhythm Society expert consensus statement on catheter and surgical ablation of atrial fibrillation","volume":"40","author":"Tzeis","year":"2024","journal-title":"J Arrhythmia"},{"key":"10.1016\/j.jacc.2026.05.033_bib204","doi-asserted-by":"crossref","DOI":"10.1016\/j.hrthm.2025.12.037","article-title":"Can oral anticoagulants be safely discontinued after atrial fibrillation ablation? A systematic review and meta-analysis of reconstructed time-to-event data","author":"Barbosa","year":"2026","journal-title":"Heart Rhythm"},{"key":"10.1016\/j.jacc.2026.05.033_bib205","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa2408308","article-title":"Left atrial appendage closure after ablation for atrial fibrillation","volume":"392","author":"Wazni","year":"2025","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jacc.2026.05.033_bib206","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1016\/j.jacc.2026.05.037","article-title":"Antiplatelet therapy in the management of atherosclerotic cardiovascular disease: 2026 ACC scientific statement","volume":"88","author":"Kumbhani","year":"2026","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib207","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1055\/s-0037-1598061","article-title":"Scoring systems for estimating the risk of anticoagulant-associated bleeding","volume":"43","author":"Parks","year":"2017","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib208","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1055\/s-0042-1750385","article-title":"Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: executive summary of a European and Asia-Pacific expert consensus paper","volume":"122","author":"Gorog","year":"2022","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib209","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.amjmed.2020.03.019","article-title":"mAF-App II Trial investigators. Regular bleeding risk assessment associated with reduction in bleeding outcomes: the mAFA-II randomized trial","volume":"133","author":"Guo","year":"2020","journal-title":"Am J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib210","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"71","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jacc.2026.05.033_bib211","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1111\/jth.13139","article-title":"Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials","volume":"13","author":"Chai-Adisaksopha","year":"2015","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib212","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2024.102584","article-title":"Safety and efficacy of direct oral anticoagulants in chronic kidney disease: a meta-analysis","volume":"8","author":"Tham","year":"2024","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib213","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1001\/jamacardio.2017.0364","article-title":"Laboratory monitoring of non-vitamin K antagonist oral anticoagulant use in patients with atrial fibrillation: a review","volume":"2","author":"Eikelboom","year":"2017","journal-title":"JAMA Cardiol"},{"key":"10.1016\/j.jacc.2026.05.033_bib214","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.ahj.2005.04.017","article-title":"Clinical classification schemes for predicting hemorrhage: results from the National Registry of Atrial Fibrillation (NRAF)","volume":"151","author":"Gage","year":"2006","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2026.05.033_bib215","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1160\/TH08-03-0193","article-title":"Predictive variables for major bleeding events in patients presenting with documented acute venous thromboembolism. Findings from the RIETE Registry","volume":"100","author":"Ru\u00edz-Gim\u00e9nez","year":"2008","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib216","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1160\/TH15-04-0350","article-title":"Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study","volume":"115","author":"Martinez","year":"2016","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib217","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib218","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus warfarin in patients with atrial fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib219","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib220","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib221","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.mayocp.2014.01.030","article-title":"Treatment discontinuations with new oral agents for long-term anticoagulation: insights from a meta-analysis of 18 randomized trials including 101,801 patients","volume":"89","author":"Chatterjee","year":"2014","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jacc.2026.05.033_bib222","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1182\/bloodadvances.2019000067","article-title":"A systematic review and meta-analysis of supplemental education in patients treated with oral anticoagulation","volume":"3","author":"Paquette","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jacc.2026.05.033_bib223","article-title":"Educational and behavioural interventions for anticoagulant therapy in patients with atrial fibrillation","volume":"4","author":"Clarkesmith","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jacc.2026.05.033_bib224","doi-asserted-by":"crossref","first-page":"4051","DOI":"10.1111\/bcp.14833","article-title":"Drug-drug interactions with warfarin: a systematic review and meta-analysis","volume":"87","author":"Wang","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacc.2026.05.033_bib225","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/j.jtha.2025.10.027","article-title":"Association of direct oral anticoagulant-anticonvulsant coprescription with clinical outcomes in older adults: a population-based cohort study","volume":"24","author":"Carlin","year":"2026","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib226","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1001\/jama.2024.3867","article-title":"Serious bleeding in patients with atrial fibrillation using diltiazem with apixaban or rivaroxaban","volume":"331","author":"Ray","year":"2024","journal-title":"JAMA"},{"key":"10.1016\/j.jacc.2026.05.033_bib227","doi-asserted-by":"crossref","DOI":"10.7326\/ANNALS-25-01408","article-title":"The risk for bleeding in patients with atrial fibrillation from concomitant use of apixaban or rivaroxaban with diltiazem compared with metoprolol","author":"Dawwas","year":"2026","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib228","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1177\/10600280251337209","article-title":"Association of direct oral anticoagulant-proton pump inhibitor co-therapy with adverse outcomes: a population-based cohort study","volume":"60","author":"Wang","year":"2026","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.jacc.2026.05.033_bib229","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1056\/NEJMoa2313040","article-title":"Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage","volume":"390","author":"Connolly","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib230","doi-asserted-by":"crossref","first-page":"4684","DOI":"10.1182\/blood-2010-04-277798","article-title":"Inhibition of the intrinsic coagulation pathway factor XI by antisense oligonucleotides: a novel antithrombotic strategy with lowered bleeding risk","volume":"116","author":"Zhang","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2026.05.033_bib231","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1111\/j.1538-7836.2011.04221.x","article-title":"Single intravenous administration of TB-402 for the prophylaxis of venous thromboembolism after total knee replacement: a dose-escalating, randomized, controlled trial","volume":"9","author":"Verhamme","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib232","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/jth.15577","article-title":"Pharmacokinetics and pharmacodynamics of abelacimab (MAA868), a novel dual inhibitor of factor XI and factor XIa","volume":"20","author":"Yi","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jacc.2026.05.033_bib233","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2018-10-880849","article-title":"MAA868, a novel FXI antibody with a unique binding mode, shows durable effects on markers of anticoagulation in humans","volume":"133","author":"Koch","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2026.05.033_bib234","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1182\/blood.2021011725","article-title":"The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial","volume":"138","author":"Lorentz","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jacc.2026.05.033_bib235","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1056\/NEJMoa2113194","article-title":"Milvexian for the prevention of venous thromboembolism","volume":"385","author":"Weitz","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib236","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1056\/NEJMoa1405760","article-title":"Factor XI antisense oligonucleotide for prevention of venous thrombosis","volume":"372","author":"B\u00fcller","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib237","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1056\/NEJMoa2105872","article-title":"Abelacimab for prevention of venous thromboembolism","volume":"385","author":"Verhamme","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib238","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa2407105","article-title":"Asundexian versus apixaban in patients with atrial fibrillation","volume":"392","author":"Piccini","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib239","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ahj.2024.08.011","article-title":"Milvexian vs apixaban for stroke prevention in atrial fibrillation: the LIBREXIA atrial fibrillation trial rationale and design","volume":"277","author":"Jain","year":"2024","journal-title":"Am Heart J"},{"key":"10.1016\/j.jacc.2026.05.033_bib240","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1056\/NEJMoa2513880","article-title":"Asundexian for secondary stroke prevention","volume":"394","author":"Sharma","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacc.2026.05.033_bib241","article-title":"Discovery and development of Factor Xa inhibitors (2015-2022)","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jacc.2026.05.033_bib242","doi-asserted-by":"crossref","first-page":"6912","DOI":"10.1038\/s41467-021-27275-8","article-title":"Efficacy and safety of next-generation tick transcriptome-derived direct thrombin inhibitors","volume":"12","author":"Koh","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.jacc.2026.05.033_bib243","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1182\/blood.2020007116","article-title":"Ciraparantag, an anticoagulant reversal drug: mechanism of action, pharmacokinetics, and reversal of anticoagulants","volume":"137","author":"Ansell","year":"2021","journal-title":"Blood"}],"container-title":["JACC"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726067008?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0735109726067008?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T14:45:45Z","timestamp":1789483545000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0735109726067008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":242,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0735109726067008"],"URL":"https:\/\/doi.org\/10.1016\/j.jacc.2026.05.033","relation":{},"ISSN":["0735-1097"],"issn-type":[{"value":"0735-1097","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Direct Oral Anticoagulants in Primary and Secondary Prevention of Thrombotic Events: 2026 ACC Scientific Statement","name":"articletitle","label":"Article Title"},{"value":"JACC","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacc.2026.05.033","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 by the American College of Cardiology Foundation","name":"copyright","label":"Copyright"}]}}